logo
8 foods that have glycerol in, as under-7s warned against slushies

8 foods that have glycerol in, as under-7s warned against slushies

Yahoo6 days ago
Slushies containing the additive glycerol should not be given to children under the age of seven, as they can make them very ill, the Food Standards Agency has warned.
The flavoured drinks, which are made of syrup and crushed ice, should also be limited to no more than 350ml a day – roughly the size of a fizzy drink can – for children aged seven to 10.
This is because "very high" levels of exposure to glycerol – which can happen when a child drinks several slushies in a short space of time – can cause shock, very low blood sugar levels and loss of consciousness, the watchdog said.
FSA chief scientific adviser Professor Robin May, warned that while children are more likely to opt for these drinks during heatwaves and hot weather, they come with risks.
"As we head into the summer holidays, we want parents to be aware of the potential risks associated with slush ice drinks containing glycerol," he said.
"While these drinks may seem harmless and side-effects are generally mild, they can, especially when consumed in large quantities over a short time, pose serious health risks to young children."
He added that the FSA was working closely with places where the drinks are sold to ensure warnings are in place.
If your child becomes unwell with nausea or headaches after drinking slushies, give them food or drink containing sugar and call 111 for medical advice. If they become drowsy or confused, call 999.
Here, we take a look at what glycerol is, its potential side-effects, and the other foods that contain it.
What is glycerol and is it safe?
Glycerol is a naturally occurring alcohol and sugar substitute that helps preserve and sweeten food, among other things.
It is also found in the intestines, attracting water to the gut, softening stools and relieving the symptoms of constipation.
In small levels, glycerol is safe – and it is an extremely common food additive. However, it can cause side-effects such as headaches, nausea, bloating, dizziness and diarrhoea.
On the skin, it might also cause redness and itching (it is found in certain skincare products and soaps).
In younger children, it has been found to lead to glycerol intoxication syndrome. Previous studies have examined the cases of 21 two- to seven-year-olds in the UK and Ireland, who required emergency care after drinking slushies.
Most of the children within the research lost consciousness and needed brain scans, and one child experienced a seizure. It also impacted their blood sugar levels and there were traces of high acidity in their blood.
While all the children were discharged from hospital and later made a full recovery, parents are now being told to avoid giving young children glycerol-filled slushies.
Eight other foods that have glycerol in them
While all of these foods are safe to eat, it's good to be aware where else you may find glycerol.
Tortilla wraps
Most wraps from the supermarket contain small quantities of glycerol, which helps sweeten the bread product and acts as a preservative.
Chewing gum
Gum formulas also include find powder lecithin (a naturally occurring emulsifier) and glycerol triacetate, which although do not add to the flavour in any way, help stabilise the gum – meaning it softens after the initial bite and helps the gum blend in the mouth.
Icing
Typically found in royal icing, glycerol – or glycerine, as it is sometimes referred to commercially – adds shine to the cake decoration and prevents it from getting hard when it sets.
Cereal bars
Again, the levels of glycerol in cereal bars is low – but it is commonly found in most breakfast or granola bars. It acts as a preservative in this instance.
Condiments
Some sauces, salad dressing, jams and preserves contain glycerol. It adds sweetness to the mixture and ensures they don't dry out. It can also improve the texture of the condiment.
Spices
Glycerol or glycerin is not naturally found in spices, but in some instances is added as a sweetener and humectant, to prevent them from drying out too much.
Ice cream
To prevent ice crystals forming in ice cream, small levels of glycerin is used to stabilise the mixture.
Canned foods
Mostly utilised in canned foods for its humectant qualities, glycerin also acts as a preservative, flavouring and colouring in canned foods.
Additional reporting by PA.
Read more about food and nutrition
Five foods and drinks that can make you feel sad (Yahoo Life UK, 4-min read)
Eight ways you can manage your child's weight as obesity rates soar in the UK (Yahoo Life UK, 4-min read)
Seven surprising health benefits of drinking coffee daily (Yahoo Life UK, 8-min read)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

European Commission approves Roche's Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation
European Commission approves Roche's Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation

Yahoo

time3 hours ago

  • Yahoo

European Commission approves Roche's Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation

Approval based on INAVO120 data showing the Itovebi™ (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone1 Up to 40% of ER-positive breast cancers have a PIK3CA mutation and are associated with poor prognosis; this approval helps address an urgent unmet need2-4 Itovebi is the first PI3K-targeted therapy to significantly extend survival, reinforcing the need for biomarker testing at diagnosis5 Basel, 23 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Itovebi™ (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment. 'Itovebi is the first treatment of its kind to improve survival outcomes for those living with PIK3CA-mutated, ER-positive advanced breast cancer,' said Levi Garraway, MD, PhD, Roche's Chief Medical Officer and Head of Global Product Development. 'Therefore, the Itovebi-based regimen may help address an important unmet need for people with this subtype of breast cancer.' The approval is based on results from the phase III INAVO120 trial, published in the New England Journal of Medicine in October 2024, which showed a 57% reduction in the risk of disease worsening or death (progression-free survival [PFS]) with the Itovebi-based regimen compared with palbociclib and fulvestrant alone (15.0 months vs. 7.3 months; hazard ratio [HR]=0.43; 95% CI: 0.32-0.59, p<0.001) in the first-line setting.1 The PFS benefit was consistent across all pre-specified subgroups and the Itovebi-based regimen was well tolerated, with no new safety signals observed.1 These results were reinforced by the INAVO120 final overall survival analysis that showed the Itovebi-based regimen reduced the risk of death by 33% (stratified HR=0.67; 95% CI: 0.48–0.94, p-value=0.0190 [boundary=0.0469]).5 Additionally, the treatment regimen substantially delayed the time to chemotherapy by approximately two years compared with palbociclib and fulvestrant alone (stratified HR=0.43; 95% CI: 0.30-0.60).5 These data were presented at the 2025 American Society of Clinical Oncology Annual Meeting and published in the New England Journal of Medicine in May 2025. Beyond INAVO120, Itovebi is currently being investigated in three company-sponsored phase III studies (INAVO121, INAVO122, INAVO123), all in PIK3CA-mutated, locally advanced or metastatic breast cancer in various combinations.6-8 We are exploring additional studies in breast cancer and other tumour types with the hope of providing the benefit of this targeted therapy to more people with PIK3CA mutations. About Itovebi TM (inavolisib)Itovebi is an oral, targeted treatment that has been shown to provide well-tolerated and durable disease control in people with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced breast cancer, who often have a poor prognosis and are in urgent need of new treatment options.1,4,9 Itovebi has been designed to help minimise the overall burden and toxicity of treatment and is differentiated from other PI3K inhibitors due to its high potency and specificity for the PI3K alpha isoform versus other isoforms, and unique mechanism of action that facilitates the degradation of mutated PI3K alpha.10,11 In addition to the European Commission's approval, the Itovebi-based regimen is also approved for the treatment of adults with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer in the United States, Switzerland, Canada, Australia, United Arab Emirates, China and Taiwan, with data from INAVO120 under review with several other global health authorities. About the INAVO120 studyThe INAVO120 study [NCT04191499] is a phase III, randomised, double-blind, placebo-controlled study evaluating the efficacy and safety of Itovebi™ (inavolisib) in combination with palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in people with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer whose disease progressed during treatment or within 12 months of completing adjuvant endocrine therapy and who have not received prior systemic therapy for metastatic disease.12 The study included 325 patients, who were randomly assigned to either the investigational or control treatment arm.12 The primary endpoint is progression-free survival, as assessed by investigators, defined as the time from randomisation in the clinical trial to the time when the disease progresses, or a patient dies from any cause.12 Secondary endpoints include overall survival, objective response rate, and clinical benefit rate.12 Beyond INAVO120, Itovebi is currently being investigated in three company-sponsored phase III clinical studies in PIK3CA-mutated locally advanced or metastatic breast cancer in various combinations: in combination with fulvestrant versus alpelisib plus fulvestrant in HR-positive/HER2-negative breast cancer post cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and endocrine combination therapy (INAVO121; NCT05646862).6 in combination with pertuzumab plus trastuzumab for subcutaneous injection (SC) versus pertuzumab plus trastuzumab for SC and optional physician's choice of endocrine therapy as a maintenance treatment in HER2-positive disease (INAVO122; NCT05894239).7 in combination with CDK4/6 inhibitor and letrozole versus placebo plus a CDK4/6 inhibitor and letrozole in the first-line setting in PIK3CA-mutated HR-positive/HER2-negative, endocrine-sensitive breast cancer (INAVO123; NCT06790693).8 About oestrogen receptor (ER)-positive breast cancerER-positive is a subtype of hormone receptor (HR)-positive breast cancer, the most prevalent type of all breast cancers, accounting for approximately 70% of cases.13,14 A defining feature of ER-positive breast cancer is that its tumour cells have receptors that attach to oestrogen, which can contribute to tumour growth.15 People diagnosed with ER-positive and HR-positive metastatic breast cancer often face the risk of disease progression and treatment side effects, creating a need for additional treatment options.14,16,17 The PI3K signalling pathway is commonly dysregulated in HR-positive breast cancer, often due to activating PIK3CA mutations, which have been identified as a potential mechanism of intrinsic resistance to standard of care endocrine therapy in combination with cyclin-dependent kinase 4/6 inhibitors.9 About Roche in breast cancerRoche has been advancing breast cancer research for more than 30 years with the goal ofhelping as many people with the disease as possible. Our medicines, along with companiondiagnostic tests, have contributed to bringing breakthrough outcomes in human epidermal growth factor 2-positive and triple-negative breast cancers. As our understanding of breast cancer biology rapidly improves, we are working to identify new biomarkers and approaches to treatment for other subtypes of the disease, including oestrogen receptor-positive breast cancer, which is a form of hormone receptor-positive breast cancer, the most prevalent type of all breast cancers.13,14 About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit All trademarks used or mentioned in this release are protected by Turner NC, et al. Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. NEJM. 2024;391(17):1584-96.[2] Cizkova M, et al. Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway. PLoS One. 2010;30;5(12):e15647.[3] Schagerholm C, et al. PIK3CA mutations in endocrine-resistant breast cancer. Scientific Reports. 2024;14:12542.[4] Fillbrunn M, et al. PIK3CA mutation status, progression and survival in advanced HR+/HER2- breast cancer: a meta-analysis of published clinical trials. BMC Cancer. 2022;22(1):1002.[5] Jhaveri KL, et al. Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer. 2025;40454641.[6] A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy (INAVO121) [Internet; cited 2025 June]. Available from: [7] A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (INAVO122) [Internet; cited 2025 June]. Available from: [8] A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/​6 Inhibitor and Letrozole vs Placebo + CDK4/​6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (INAVO123) [Internet; cited 2025 June]. Available from: Anderson E, et al. A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer. Int J Breast Cancer. 2020;2020:3759179.[10] Juric D, et al. A phase I/Ib study of inavolisib (GDC-0077) in combination with fulvestrant in patients (pts) with PIK3CA-mutated hormone receptor-positive/HER2-negative (HR+/HER2–) metastatic breast cancer. Presented at San Antonio Breast Cancer Symposium, 2020 December 7-10; San Antonio, USA. Abstract #P5-17-05.[11] Hong R, et al. GDC-0077 is a selective PI3K alpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies. Cancer Res. 2018;78(4):4-14.[12] A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer (INAVO120) [Internet; cited 2025 June]. Available from: National Cancer Institute: Surveillance, Epidemiology and Ends Result Program. Cancer Stat Facts: Female Breast Cancer Subtypes [Internet; cited 2025 June]. Available from: Lim E, et al. The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park). 2012;26(8):688-94,696.[15] Wu VS, et al. From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer? J Steroid Biochem Mol Biol. 2015 Sep;153:45-53.[16] Tomas R and Barrios CH. Optimal management of hormone receptor positive metastatic breast cancer in 2016. Ther Adv Med Oncol. 2015;7(6):304-20.[17] Galipeau N, et al. Understanding key symptoms, side effects, and impacts of HR+/HER- advanced breast cancer: qualitative study findings. J Patient-Rep Outcomes. 2019;3(1): Global Media RelationsPhone: +41 61 688 8888 / e-mail: Hans Trees, PhDPhone: +41 79 407 72 58 Sileia UrechPhone: +41 79 935 81 48 Nathalie AltermattPhone: +41 79 771 05 25 Lorena CorfasPhone: +41 79 568 24 95 Simon GoldsboroughPhone: +44 797 32 72 915 Karsten KleinePhone: +41 79 461 86 83 Kirti PandeyPhone: +49 172 6367262 Yvette PetillonPhone: +41 79 961 92 50 Dr Rebekka SchnellPhone: +41 79 205 27 03 Roche Investor Relations Dr Bruno EschliPhone: +41 61 68-75284e-mail: Dr Sabine BorngräberPhone: +41 61 68-88027e-mail: Dr Birgit MasjostPhone: +41 61 68-84814e-mail: Investor Relations North America Loren KalmPhone: +1 650 225 3217e-mail: Attachment Media Investor Release EC approves Itovebi English

I'm A 52-Year-Old Trainer, And I Think This 15-Minute Routine Is The 'Only' Arms Workout Women Need
I'm A 52-Year-Old Trainer, And I Think This 15-Minute Routine Is The 'Only' Arms Workout Women Need

Yahoo

time3 hours ago

  • Yahoo

I'm A 52-Year-Old Trainer, And I Think This 15-Minute Routine Is The 'Only' Arms Workout Women Need

If anyone can tell you how to get results from your workouts, it's Caroline Idiens. At 52, she has over 20 years of experience as a personal trainer, including five years heading up her online fitness platform Caroline's Circuits, specializing in 30-minute home strength workouts. But half of that time is enough to build your arms, Idiens says. "This may be controversial, but I think (know) this is the ONLY arms workout you need at home," she says of her go-to 15-minute routine. "All you need are a set of dumbbells. Take a 30-sec rest between exercises and try three sets in total. Go slow and warm up first. I'm using 5 kgs, but use the weight that is right for you." Here's exactly which exercises to do and how many reps to go for... Best 15-minute arm workout for women Around the worlds. Do: 10 reps x 3 Hold a kettlebell or dumbbell with both hands, keeping your arms extended in front of you. Stand with feet shoulder-width apart, maintaining a stable and upright posture. Initiate the movement by passing the weight around your body, from front to back, in a circular motion. Keep the movement fluid and controlled, maintaining a stable core front raises. Do: 12 reps x 3 Stand with your feet hip-width apart, holding a dumbbell in each hand with palms facing your body. Keep your arms straight (with a slight bend in the elbows) and lift one arm forward and up to shoulder height, while keeping the other arm at your side. Lower the raised arm with control and repeat on the opposite side. That's one rep; alternate sides for the total number of raises. Do: 10 reps x 3 Stand with a dumbbell in each hand, arms by your sides, palms facing inwards. Ensure your shoulders are relaxed (not raised), your abs are engaged (think tensing, as opposed to breathing in), and there's a slight bend in your knees. Retaining this posture, lift the dumbbells out to the sides with straight arms, going no higher than shoulder height. Gradually (i.e. don't just let your arms fall back down, move with control) lower the dumbbells to the starting shoulder press. Do: 12 reps x 3 Stand with feet shoulder-width apart, holding a dumbbell in each hand at shoulder height with palms facing each other. A Alternately press one dumbbell overhead, extending the arm fully, while keeping the other dumbbell at shoulder height. Lower the raised arm back to the starting position and repeat on the other side, continuing to flies. Do 10 reps x3 Stand with your feet at a hip-width distance with a soft bend in your knees. With a neutral spine, hinge at the waist so your chest is lowered to near parallel with the floor and your hips come slightly backwards. With your arms straight down towards the floor, hold the dumbbells comfortably in your hands with a neutral grip (palms facing in towards each other). Have a soft bend in your elbows as you raise the weights up and out to the sides, in line with your shoulders; at this point, your palms should be facing down to the floor. Squeeze your upper back and in between your shoulder blades to assist the movement. Control the movement as you lower the weights back to the starting kickbacks. Do: 12 reps x 3 Stand with your knees bent and lean forward slightly, with a dumbbell in each hand. Keeping your back straight, bend your dumbell-holding arm 90 degrees at the elbow so your triceps are aligned with your back and your biceps are perpendicular to the floor. Engage your core and your triceps and hinge at the elbow, lifting the dumbbell up and back as you try and straighten your arm. Your triceps should stay still; only your elbow moves. Guide the weight upward until your arm is straight, pause, then lower back to 90 degrees. That's one curls. Do 10 reps x 3 Stand with your feet hip-width apart, holding weights in front of you, palms facing forward. Without moving your upper arms, slowly curl the weights toward your shoulders. At the top of the curl, rotate your wrists inward so your palms face forward. Slowly lower them in that position. Rotate your wrists and dumbbells back to the starting position. That's one Arnold press. Do: 8 each side x 3 Take a dumbbell in each hand. Stand with a shoulder-width stance and brace your core. Raise the dumbbells so they're shoulder height with your palms facing your body. Pull your shoulder blades back and down, then extend your arms up while rotating your wrists to the front, so that you end up with the dumbbells above your head with palms facing forward. Remaining stable, slowly lower the dumbbells and rotate the wrists so that the palms are facing towards you chest press. Do: 8 reps x 3 Stand with feet shoulder-width apart, holding a dumbbell in each hand at shoulder height, palms facing forward. Keeping your arms bent, bring your elbows and palms to touch while holding the dumbbells in the same position. Then open your arms back to the starting position, maintaining the same angle. That's one rep. Get the Workouts Get the Challenge Get the Workouts Get the Workouts Get the Challenge Get the Workouts Get the Challenge Get the Workouts Get the Workouts Get the Workouts Get the Workouts Get the Workouts Get the Workouts Get the Workouts Get the Challenge Get the Workouts You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals

ImmunityBio's (IBRX) ANKTIVA Gets Approved by UK's Medicines and Healthcare Regulatory Agency
ImmunityBio's (IBRX) ANKTIVA Gets Approved by UK's Medicines and Healthcare Regulatory Agency

Yahoo

time4 hours ago

  • Yahoo

ImmunityBio's (IBRX) ANKTIVA Gets Approved by UK's Medicines and Healthcare Regulatory Agency

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the . On July 8, ImmunityBio, Inc. (NASDAQ:IBRX) announced that the UK's Medicines and Healthcare products Regulatory Agency has approved ANKTIVA with Bacillus Calmette-Guérin for treating certain bladder cancer patients. This is significant as it marks the first approval for the company outside of the United States of America. Moreover, the drug is a first-in-class IL-15 agonist, which works by activating and multiplying immune cells, specifically NK cells and T cells that help the body fight cancer. A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents. In addition, clinical studies have shown strong results as some patients maintained a complete response for over 47 months at the last review. ImmunityBio, Inc. (NASDAQ:IBRX) is a biopharmaceutical company that develops therapies and vaccines that boost the immune system to fight cancer and infectious diseases. While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store